BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it has entered into a new agreement with Medline Industries, Inc. to commercialize the Company’s advanced wound care product - Hyalomatrix®, in the United States on an exclusive basis through 2019. According to the agreement, Anika will receive product payment and royalty revenues from the sale of the product by Medline. Hyalomatrix® is a biologically-derived matrix for in-growing cells, and has the U.S. Food and Drug Administration marketing clearance.
Help employers find you! Check out all the jobs and post your resume.
